Taking pravastatin for 3 months didn't raise or lower average blood sugar or long-term glucose control in kidney transplant patients without diabetes.

47

Pro

0

Against

Evidence from Studies

Supporting (1)

47

Community contributions welcome

47

#2667 The effect of pravastatin on insulin resistance in kidney transplant recipients. A randomized, placebo-controlled cross over trial

Randomized Controlled Trial

Human

This study gave 11 non-diabetic kidney transplant patients pravastatin for 12 weeks and found their blood sugar and HbA1c levels didn’t change compared to when they took a placebo—so pravastatin doesn’t mess with their blood sugar at this dose.

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

#2667 The effect of pravastatin on insulin resistance in kidney transplant recipients. A randomized, placebo-controlled cross over trial

Score: 47

DOI: 10.1093/ndt/gfaf116.1800

Similar Assertions

After drinking a sugary solution, pravastatin didn't make blood sugar rise more or less than a placebo in kidney transplant patients without diabetes.

47

0

92%

Taking pravastatin for 3 months didn’t raise or lower average blood sugar or long-term blood sugar control in people with early kidney disease who don’t have diabetes.

47

0

91%

Taking pravastatin for 12 weeks didn't make the body better or worse at using insulin to control blood sugar in people who had a kidney transplant and don't have diabetes.

47

0

90%

Taking pravastatin for 3 months didn't harm the transplanted kidney's ability to work in patients without diabetes.

47

0

89%

Taking pravastatin for 12 weeks didn’t make the body better or worse at using insulin to control blood sugar in people with early-stage kidney disease who don’t have diabetes.

47

0

83%